Evidence map›Paper›PMID 40535124›Full record

ArticleFrontiers in oncology2025

LASSO-Cox model in the prognostic evaluation of radiochemotherapy efficacy for lymph node metastatic nasopharyngeal carcinoma.

Simin Lu, Xin Zhang, Xin Zheng, Gang Li, Haizhen Zhang, Yinghong Zhong, Daijie Wang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Simin LuDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Xin ZhangDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Xin ZhengDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Gang LiDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Haizhen ZhangDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Yinghong ZhongDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.
Daijie WangDepartment of Oncology, Luzhou People's Hospital, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This retrospective study aimed to develop and validate a prognostic evaluation system based on the LASSO-Cox regression model for nasopharyngeal carcinoma (NPC) patients undergoing radiochemotherapy. Methods: Data from 186 patients treated between 2013 and 2019 at three tertiary hospitals in China were analyzed. Patients were randomly divided into a training set and a validation set in a 7:3 ratio. In the training cohort, the LASSO + Cox regression analysis was conducted to identify independent prognostic factors influencing progression-free survival (PFS). Based on these independent factors, a nomogram was constructed to predict 2-, 3-, and 5-year PFS. The predictive performance of the nomogram was then evaluated in the validation cohort. Results: Using the LASSO method for variable selection, three prognostic indicators were initially identified, and stepwise Cox regression in the training cohort further confirmed that clinical stage and EBV level were independent predictors of PFS. A nomogram was constructed based on these factors, which achieved areas under the receiver operating characteristic curves (AUC-ROC) of 0.801, 0.760, and 0.749 for predicting 2-, 3-, and 5-year PFS, respectively, in the validation cohort. The model also demonstrated robust performance through calibration and decision curve analyses. Conclusions: This nomogram provides a practical tool for personalized risk assessment and treatment planning, facilitating early identification of high-risk patients who may benefit from intensified treatment strategies.

Indexed as

LASSO-Coxlymph node metastaticnasopharyngeal carcinomanomogramradiochemotherapy

Identifiers

PMID40535124
PMCPMC12174080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.